Disposition of [G-3H]paclitaxel and cremophor EL in a patient with severely impaired renal function

Drug Metabolism and Disposition

Volumn 27, Issue 11, 1999, Pages 1300-1305

  Gelderblom, Hans ^a   Verweij, Jaap ^a   Brouwer, Eric ^a   Pillay, Marrimuthoo ^a   De Bruijn, Peter ^a   Nooter, Kees ^a   Stoter, Gerrit ^a   Sparreboom, Alex ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CREATININE; CREMOPHOR; PACLITAXEL;

AGED; AREA UNDER THE CURVE; ARTICLE; CASE REPORT; DRUG DISPOSITION; DRUG EXCRETION; DRUG HALF LIFE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASE; OVARY CANCER; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; URINARY EXCRETION;

AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; GLYCEROL; HUMANS; NEPHROSCLEROSIS; OVARIAN NEOPLASMS; PACLITAXEL; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 0032734467     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Anderson CD, Wang J, Kumar GN, McMillan JM, Walle UK and Walle T (1995) Dexamethasone induction of taxol metabolism in the rat. Drug Metab Dispos 23:1286-1290.
2. Balat O, Kudelka AP, Edwards CL, Verschraegen C, Mante R and Kavanagh JJ (1996) A case report of paclitaxel administered to a patient with platinum-refractory ovarian cancer on long-term hemodialysis. Eur J Gynaecol Oncol 17:232-233.
3. Brouwer E, Verweij J, Hauns B, Loos WJ, Nooter K, Mross K, Stoter G and Sparreboom A (1998) Linearized colorimetric assay for Cremophor EL: Application to pharmacokinetics afler 1-hour paclitaxel infusions. Anal Biochem 261:198-202.
4. Conley BA, Zaharski D, Kearns CM, Rosen DM, Van Echo DA and Egorin MJ (1997) Paclitaxel pharmacokinetic/pharmacodynamic relationships in patients with renal dysfunction (Abstract). Proc Am Soc Clin Oncol 16:233a.
5. Cresteil T, Monsarrat B, Alvinerie P, Treluyer M, Viera I and Wright M (1994) Taxol metabolism by human liver microsomes: Identification of cytochrome P450 involved in its biotransformation. Cancer Res 54:386-392.
6. Fazeny B, Olsen SJ, Willey T, Stewart MB, Dittrich E, Huber H and Dittrich C (1995) Pharmacokinetic assessment of paclitaxel in an ovarian cancer patient on hemodialysis (Abstract). Proc Am Soc Clin Oncol 14:173.
7. Gianni L, Kearns CM, Giani AN, Capri G, Vigano L, Locatelli A, Bonadonna G and Egorin MJ (1995) Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/ pharmacodynamic relationships in humans. J Clin Oncol 13:180-190.
8. Harris JW, Katki A, Anderson LW, Chmurny GN, Paukstelis JV and Collins JM (1994a) Isolation, structural determination, and biological activity of 6α-hydroxytaxol, the principal human metabolite of taxol. J Med Chem 37:706-709.
9. Harris JW, Rahman A, Kim BR, Guengerich FP and Collins JM (1994b) Metabolism of taxol by hepatic microsomes and liver slices: Participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res 54:4026-4035.
10. Kumar GN, Walle UK and Walle T (1994) Cytochrome P450 mediated human liver microsomal taxol 6A hydroxylation. J Pharmacol Exp Ther 268:1160-1165.
11. McGuire WP, Rowinsky EK, Rosenshein NB, Grumbine FC, Ettinger DS, Armstrong DK and Donehower RC (1989) Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111:273-279.
12. Monsarrat B, Alvinerie P, Wright M, Dubois J, Guéritte-Voegelein F, Guénard D, Donehower RC and Rowinsky EK (1993) Hepatic metabolism and biliary excretion of taxol in rats and human. J Natl Cancer Inst Monogr 15:39-46.
13. Monsarrat B, Chatelut E, Royer I, Alvinerie P, Dubois J, Dezeuse A, Roche H, Cros S, Wright M and Canal P (1998) Modification of paclitaxel metabolism in a cancer patient by induction of cytochrome P450 3A4. Drug Metab Dispos 26:229-233.
14. Ozols RF (1998) Chemotherapy of ovarian cancer. Cancer Treat Res 95:219-234.
15. Rahman A, Korzekwa KR, Grogan J, Gonzalez FJ and Harris JW (1994) Selective biotransformation of taxol to 6α-hydroxylaxol by human cytochrome P450 2C8. Cancer Res 54:5543-5546.
16. Rangel C, Niell H, Miller A and Cox C (1994) Taxol and taxotere in bladder cancer: In vitro activity and urine stability. Cancer Chemother Pharmacol 33:460-464.
17. Rowinsky EK (1995) Pharmacology and metabolism, in Paclitaxel in Cancer Treatment (McGuire WP and Rowinsky EK eds) pp 91-120, Marcel Dekker, New York.
18. Royer I, Alvinerie P, Armand JP, Ho LK, Wright M and Monsarrat B (1995) Paclitaxel metabolites in human plasma and urine: Identification of 6α-hydroxytaxol, 7-epitaxol and taxol hydrolysis products using liquid chromatography/atmospheric-pressure chemical ionization mass spectrometry. Rapid Commun Mass Spectrom 9:495-502.
19. Schilder LE, Egorin MJ, Zuhowski EG and Rossof AH (1994)The pharmacokinetics of taxol in a dialysis patient (Abstract). Proc Am Soc Clin Oncol 13:136.
20. Sonnichsen DS and Relling MV (1994) Clinical pharmacokinetics of paclitaxel. Clin Pharmacokinet 24:256-269.
21. Sparreboom A, De Bruijn P, Nooter K, Loos WJ, Stoter G and Verweij J (1998a) Determination of paclitaxel in human plasma using single solvent extraction before isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection. J Chrontatogr Biomed Sci Appl 705:159-164.
22. Sparreboom A, Huizing MT, Boessen JJB, Nooijen WJ, Van Tellingen O and Beijnen JH (1995) Isolation, purification and biological activity of mono-and dihydroxylated paclitaxel metabolites from human feces. Cancer Chemother Pharmacol 36:299-304.
23. Sparreboom A, Loos WJ, Verweij J, De Vos AI, Van der Burg MEL, Stoter O and Nooter K (1998b) Quantitation of Cremophor EL in human plasma samples using a colorimetric dye-binding microassay. Anal Biochem 255:171-175.
24. Sparreboom A, Van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DKF, Borst P, Nooijen WJ, Beijnen JH and Van Tellingen O (1997) Limited oral bioavailabilily and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 94:2031-2035.
25. Sparreboom A, Van Tellingen O, Nooijen WJ and Beijnen JH (1996) Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res 56:2112-2115.
26. Sparreboom A, Van Zuylen L, Brouwer E, Loos WJ, De Bruijn P, Gelderblom H, Pillay M, Nooler K, Stoter G and Verweij J (1999) Cremophor EL-mediated alteration of paclitaxel distribution in human blood: Clinical pharmacokinetic implications. Cancer Res 59:1454-1457.
27. Sparreboom A, Verweij J, Van der Burg MEL, Loos WJ, Brouwer E, Vigano L, Locatelli A, De Vos AI, Nooter K, Stoter G and Gianni L (1998c) Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo. Clin Cancer Res 4:1937-1942.
28. Venook AP, Egorin MJ, Rosner GL, Brown TD, Jahan TM, Batist G, Hohl R, Budman D, Ratain MJ, Kearns CM and Schilsky RL (1998) Phase 1 and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and leukemia group B9264. J Clin Oncol 16:1811-1819.
29. Walle T, Walle UK, Kumar GN and Bhalla KN (1995) Taxol metabolism and disposition in cancer patients. Drug Metab Dispos 23:506-512.
30. Wiseman LR and Spencer CM (1998) Paclitaxel. An update of its use in the treatment of metastatic breast cancer and ovarian and other gynaecological cancers. Drug Aging 12:305-334.
31. Woo MH, Gregornik D, Shearer PD, Meyer WH and Relling MV (1999) Pharmacokinetics of paclitaxel in an anephric patient. Cancer Chemother Pharmacol 43:92-96.